Integrated Hypertension and Diabetes Mellitus Type II Treatment and Care Among People Living With HIV/AIDS

Integrated Hypertension and Diabetes Mellitus Type II Treatment and Care Among People Living With HIV/AIDS Attending Care and Treatment Center in Dar es Salaam, Tanzania

This project was a facility-based program intervention for People Living with HIV (PLHIV) aged 18 years and above who attended a Care and Treatment Center (CTC) in Dar es Salaam, Tanzania. Clients received preventive, diagnostic, and treatment services for Hypertension (HTN) and Type Two Diabetes Mellitus (T2DM). The primary health outcomes were all-cause mortality, disease-specific morbidity, HTN, and T2DM control rates. Secondary outcomes included access to care, retention in care adherence, and quality of care. Results obtained can be used to strengthen Non-Communicable Diseases (NCDs) care delivery in HIV/AIDS care in CTC in Tanzania.

Study Overview

• Status: Completed
• Conditions: HIV Infections; Hypertension; Diabetes Mellitus
• Intervention / Treatment: Diagnostic test: Biochemical, weight measurements, Blood pressure and blood sugar level

Detailed Description

A cohort of patients who were diagnosed with hypertension and diabetes was created and followed up for 6 months. Patients were required to attend clinics on a monthly basis. At the first visit short interview using the STEPwise approach of the STEPS surveillance tool for NCDs from the World Health Organization (WHO) was conducted. On subsequent visits, hypertension and blood sugar levels and cholesterol levels will be measured and adherence to medication were assessed. The patient registry was developed following recommendations from the HEARTS (Healthy lifestyle, Evidence-based protocols, Access to essential medicines and technology, Risk-based Cardiovascular Disease (CVD) management, Team-based care Guidance Systems for monitoring)technical package of WHO with some modifications if needed. A simple surveillance system was developed for all patients diagnosed with hypertension and diabetes so that there is continuous evaluation and monitoring of all patients attending NCDs care at the HIV clinic.

• Study Type: Observational
• Enrollment (Actual): 333

Contacts and Locations

Study Locations

• Tanzania
  • Dar Es Salaam, Tanzania
    • Temeke Regional Referral Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 54 years (Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The target population was PLHIV aged 18 years or above attending Temeke RRH in Temeke District in Dar es Salaam, Tanzania. We used convinient sampling to select PLHIV who attended CTC within the 5 days of data collection. Clients were randomly selected based on availability at the time of interview. The project excluded pregnant women living with HIV/AIDS and patients with mental diseases.

Description

Inclusion Criteria:

All PLHIV who attended CTC 18 years and above

Exclusion Criteria:

• Pregnant women living with HIV/AIDS
• Patients with mental diseases.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CHANGE IN BLOOD PRESSURE LEVEL	Change in the mean blood pressure at the beginning and the end of the study	SIX MONTHS

Collaborators and Investigators

• Sponsor: Muhimbili University of Health and Allied Sciences
• Investigators: Principal Investigator: Atuganile Musyani, Masters, Muhimbili University of Health and Allied Sciences

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2020
• Primary Completion (Actual): June 30, 2020
• Study Completion (Actual): June 30, 2020

Study Registration Dates

• First Submitted: March 12, 2023
• First Submitted That Met QC Criteria: March 25, 2023
• First Posted (Actual): March 27, 2023

Study Record Updates

• Last Update Posted (Actual): May 8, 2023
• Last Update Submitted That Met QC Criteria: May 5, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hypertension; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: MUHAS-REC-1-2020-074

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No